However, we believe our selection of inflammatory markers is reflective of the tumour-inflammation axis on a systemic level, and we could show that both cellular inflammatory biomarkers like the LMR and plasmatic biomarkers like CRP were effective in predicting survival and therapy response in our cohort. The gene discussed is CRP; the disease is neoplasm.